Uptake of lactosylated low-density lipoprotein by galactose-specific receptors in rat liver.
The liver contains two types of galactose receptors, specific for Kupffer and parenchymal cells respectively. These receptors are only expressed in the liver, and therefore are attractive targets for the specific delivery of drugs. We provided low-density lipoprotein (LDL), a particle with a diameter of 23 nm in which a variety of drugs can be incorporated, with terminal galactose residues by lactosylation. Radioiodinated LDL, lactosylated to various extents (60-400 mol of lactose/ mol of LDL), was injected into rats. The plasma clearance and hepatic uptake of radioactivity were correlated with the extent of lactosylation. Highly lactosylated LDL (greater than 300 lactose/LDL) is completely cleared from the blood by liver within 10 min. Pre-injection with N-acetylgalactosamine blocks liver uptake, which indicates that the hepatic recognition sites are galactose-specific. The hepatic uptake occurs mainly by parenchymal and Kupffer cells. At a low degree of lactosylation, approx. 60 lactose/LDL, the specific uptake (ng/mg of cell protein) is 28 times higher in Kupffer cells than in parenchymal cells. However, because of their much larger mass, parenchymal cells are the main site of uptake. At high degrees of lactosylation (greater than 300 lactose/LDL), the specific uptake in Kupffer cells is 70-95 times that in parenchymal cells. Under these conditions, Kupffer cells are, despite their much smaller mass, the main site of uptake. Thus not only the size but also the surface density of galactose on lactosylated LDL is important for the balance of uptake between Kupffer and parenchymal cells. This knowledge should allow us to design particulate galactose-bearing carriers for the rapid transport of various drugs to either parenchymal cells or Kupffer cells.
Bijsterbosch
M K
MK
Center for Bio-Pharmaceutical Sciences, University of Leiden, The Netherlands.
Van Berkel
T J
TJ
D000116:Acetylgalactosamine / Q000494:pharmacology; D000117:Acetylglucosamine / Q000494:pharmacology; D000818:Animals; D001212:Asialoglycoproteins; D002451:Cell Compartmentation; D060748:Fetuins; D005690:Galactose / Q000378:metabolism*; D019791:Guanidine; D006146:Guanidines / Q000494:pharmacology; D007785:Lactose; D008077:Lipoproteins, LDL / Q000378:metabolism* / Q000493:pharmacokinetics; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D051381:Rats; D011919:Rats, Inbred Strains; D011956:Receptors, Cell Surface / Q000378:metabolism*; D000509:alpha-Fetoproteins / Q000494:pharmacology
D001212:Asialoglycoproteins; D060748:Fetuins; D006146:Guanidines; D008077:Lipoproteins, LDL; D011956:Receptors, Cell Surface; D000509:alpha-Fetoproteins; C017029:asialofetuin; C039707:galactose receptor; D007785:Lactose; D019791:Guanidine; D000116:Acetylgalactosamine; D000117:Acetylglucosamine; D005690:Galactose